Myostatin Inhibitor vs PEG-MGF
A side-by-side research comparison of Myostatin Inhibitor and PEG-MGF across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Myostatin Inhibitor | PEG-MGF |
|---|---|---|
| Full name | Myostatin Inhibitor Peptides (Anti-GDF-8) | PEGylated Mechano Growth Factor |
| Category | Muscle Growth | Muscle Growth |
| Status | Research compound | Research compound |
| Mechanism | Propeptide mimics bind mature myostatin; peptide aptamers block ActRIIB; small antagonists compete for receptor. All prevent myostatin-mediated suppression of muscle growth. | PEGylation protects MGF from rapid degradation, extending half-life from minutes to hours. Activates satellite cells systemically for whole-body muscle recovery. |
| Molecular weight | 2,000-15,000 Da (varies) | ~5000 Da (with PEG) |
| Half-life | 4-48 hours (design-dependent) | ~30 minutes to several hours (vs 5-7 min native) |
| Bioavailability | Variable (SubQ) | ~85% subcutaneous |
| Typical dose | 50-500 mcg | 100-200 mcg |
| Frequency | 3-7x per week | 2-3x per week |
| Route | Subcutaneous | Subcutaneous injection |
Myostatin Inhibitor reported benefits
- Muscle growth promotion
- Strength increase
- Myostatin blockade
- Muscle wasting treatment potential
- Metabolic improvement
PEG-MGF reported benefits
- Extended half-life vs native MGF
- Systemic satellite cell activation
- Whole-body recovery
- Less frequent dosing
Related comparisons
Research and educational reference only. Not medical advice.